Imiquimod

Generic Name
Imiquimod
Brand Names
Aldara, Vyloma, Zyclara
Drug Type
Small Molecule
Chemical Formula
C14H16N4
CAS Number
99011-02-6
Unique Ingredient Identifier
P1QW714R7M
Background

Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and cont...

Indication

For the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Also indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above.

Associated Conditions
Actinic Keratoses of the face, Actinic Keratoses of the scalp, Condylomata Acuminata, Herpes Simplex Infections, Molluscum Contagiosum, Superficial Basal Cell Carcinoma
Associated Therapies
-
Clinical Trials
Related News

Randomized Clinical Trial Evaluating the Efficacy of Topical Imiquimod in High Grade Cervical Intraepithelial Lesions

First Posted Date
2017-07-28
Last Posted Date
2021-02-17
Lead Sponsor
Barretos Cancer Hospital
Target Recruit Count
90
Registration Number
NCT03233412
Locations
🇧🇷

Barretos Cancer Hospital, Barretos, Brazil

Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia

First Posted Date
2017-06-22
Last Posted Date
2024-05-08
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
13
Registration Number
NCT03196180
Locations
🇺🇸

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

CTCL Directed Therapy

First Posted Date
2017-04-17
Last Posted Date
2019-08-13
Lead Sponsor
James J. Peters Veterans Affairs Medical Center
Target Recruit Count
8
Registration Number
NCT03116659
Locations
🇺🇸

James J Peters Bronx Veterans Affairs Medical Center, Bronx, New York, United States

Topical Challenge With Omiganan and Imiquimod in Healthy Volunteers

First Posted Date
2017-03-07
Last Posted Date
2017-05-22
Lead Sponsor
Maruho Co., Ltd.
Target Recruit Count
16
Registration Number
NCT03071679
Locations
🇳🇱

LUMC/Centre for Human Drug Research, Leiden, Netherlands

Imiquimod Treatment of High-grade CIN

First Posted Date
2016-09-28
Last Posted Date
2018-08-16
Lead Sponsor
Maastricht University Medical Center
Target Recruit Count
120
Registration Number
NCT02917746
Locations
🇳🇱

Meander Medical Center, Amersfoort, Netherlands

🇳🇱

Erasmus Medical Center, Rotterdam, Netherlands

🇳🇱

Maastricht University Medical Center, Maastricht, Netherlands

Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3)

First Posted Date
2016-08-11
Last Posted Date
2024-05-02
Lead Sponsor
Yale University
Target Recruit Count
134
Registration Number
NCT02864147
Locations
🇺🇸

Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States

iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL

First Posted Date
2016-06-16
Last Posted Date
2022-11-28
Lead Sponsor
University Hospital Tuebingen
Target Recruit Count
56
Registration Number
NCT02802943
Locations
🇩🇪

Robert-Bosch-Krankenhaus Abteilung fuer Haematologie, Onkologie und Palliativmedizin, Stuttgart, Baden-Wuerttemberg, Germany

🇩🇪

Marienhospital, Stuttgart, Baden-Württemberg, Germany

🇩🇪

Katharinenhospital, Stuttgart, BW, Germany

and more 2 locations

Imiquimod Treatment of Residual or Recurrent CIN Lesions: a Study Protocol

First Posted Date
2016-02-01
Last Posted Date
2018-02-06
Lead Sponsor
Erasmus Medical Center
Target Recruit Count
433
Registration Number
NCT02669459
Locations
🇳🇱

Erasmus Medical center, Rotterdam, Zuid-Holland, Netherlands

Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer

First Posted Date
2015-11-09
Last Posted Date
2024-06-12
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
150
Registration Number
NCT02600949
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy

First Posted Date
2015-05-22
Last Posted Date
2017-08-17
Lead Sponsor
University Hospital Tuebingen
Target Recruit Count
36
Registration Number
NCT02452307
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy